Navigation Links
New platinum-phosphate compounds kill ovarian cancer cells
Date:11/19/2008

ATHENS, Ohio (Nov. 19, 2008) A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences.

The compounds could be less harmful than current cancer treatments on the market such as cisplatin and carboplatin because they don't penetrate the cell nucleus and attach to DNA, said lead author Rathindra Bose. Conventional drugs can interfere with the functions of the cell's enzymes, which lead to side effects such as hearing and hair loss and kidney dysfunction.

Though scientists don't fully understand the mechanism by which the phosphaplatins kill cancer cells, they suspect that the compounds bind to the cell surface membrane proteins and transmit a "death signal" to the interior of the cell, Bose said. The compounds are created by attaching platinum to a phosphate ligand, which can readily anchor to the cell membrane. Future studies will focus on identifying the exact process.

"The findings suggest a paradigm shift in potential molecular targets for platinum anticancer drugs and in their strategic development," said Bose, a professor of biomedical sciences and chemistry and vice president for research at Ohio University who conducted the work while at Northern Illinois University.

The first drug developed for the treatment of ovarian and testicular cancers, cisplatin, was approved for use in 1982. Though it's 95 percent effective, it works best during the early stages of the disease, and some patients develop a resistance to it. Two drugs introduced later, carboplatin and oxaliplatin (which is used for colorectal cancer), overcame some of those problems, but their potency can harm the immune system of patients, said Bose, who has been studying alternative compounds and targets for these cancers for 25 ye
'/>"/>

Contact: Andrea Gibson
gibsona@ohio.edu
740-597-2166
Ohio University
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
2. Organon Signs an Exclusive, Worldwide Licence Agreement on Advanced Antithrombotic Compounds With Endotis Pharma
3. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
4. Novel Compounds May Battle Diseases of Aging
5. Bionovo Describes a New Class of Therapeutic Compounds
6. Active compounds found in Ganoderma lucidum fungus with potential to treat prostate cancer
7. Research discovers new compounds active against tuberculosis and malaria
8. Researcher of the University of Navarra discovered potential antidepressant compounds
9. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
10. Stevens chemists identify compounds to lure nutria, a rat-like pest ravaging Gulf Coast wetlands
11. Drosophila drug screen for fragile X syndrome finds promising compounds and potential drug targets

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...elleMedicalInc.,aleadingmanufacturerofbreastMRIcoi...newleadingedgeclinicalapplicationsonitsAegis(TM)me...alSocietyofNorthAmerica(RSNA)annualmeetinginChicag...nsleveragetheuniquehighqualityimagesgeneratedbySen...pleimagingmodalitiesformulti-parametricassessment....
(Date:11/25/2009)...TheBayAreaAirQualityManagementDistrictisissuingthe...rt forThursday,November26,2009whichbansburningwo...oorsandoutdoors. ,, "Cold,stillweatherwillcontr...ent,executiveofficeroftheAirDistrict."We,reaskingB...ndfellowcommunitymembersthisThanksgiving,andnottob...
(Date:11/25/2009)...of a collaboration between UCLA engineers and phys...10 million Americans who suffer from peripheral ar... the arteries, peripheral arterial disease, or PAD...d arteries reduce blood flow to the limbs. The con...se, heart attack and stroke, and its progression c...
(Date:11/25/2009)...treatment clinics to resume Monday, Nov. 30 , ..., 2009 -- Centegra Health System is continuing to ...t four Centegra Primary Care (CPC) vaccination cli.... The clinics are at CPC sites in Huntley, Woodsto...ollows: ,   From 4:30 to 7:30 p.m. Tue...
(Date:11/25/2009)...IONSkincare ®isproudtosupportGNC,seffortstora...St.Jude ThanksandGiving campaign,$1fromthepurchase...pBalm willbedonatedtoSt.Jude.Additionally,GNCcusto...heckoutatoneoftheir5,000+retaillocationsoratGNC.co...their2009 ThanksandGiving campaign. ,, "Wearede...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2
... hormone released during act reinforces maternal b...- Mothers who breast-feed are less likely to negle..., In their study, the scientists followed 7,223 Au...reast-fed for less than four months were twice as ...
...ith a particular gene variant may be more likely t...n people without the gene, according to a study pu...eurology , the medical journal of the American Aca...rme, the most common type of brain cancer. People ...
... having a private well or septic system, and other... risk factors for bacterial intestinal infections ...o food, such as the current Salmonella outbreak ...ically termed as enteric infections. The new study...
...eased 19% to $80.8 Million and EPS Increased to $1...k Repurchase Program for up to One Million Shares ...ves, Inc. (Nasdaq: MTXX ), a healthcare company ...its fiscal 2009 third quarter and nine months ende...
...ing to its strong executive team, Halo Pharmaceuti...ston, a thirty-five year pharmaceutical industry v...evelopment. Al comes to Halo from a long and dist...n of Al to the Halo business development team is a...
...e, third of popular sweetened products showed trac... Almost half of tested samples of commercial high-...h was also found in nearly a third of 55 popular b...aced sugar as the sweetener in many beverages and ...
Other Medicine News:Health News:Moms Who Breast-Feed Less Likely to Neglect Child 2Health News:Was it the chicken salad or the swim? 2Health News:Was it the chicken salad or the swim? 3Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 2Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 3Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 4Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 5Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 6Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 7Health News:Halo Pharmaceutical Welcomes Al Rosenston as its Vice President, Business Development 2Health News:Study Finds High-Fructose Corn Syrup Contains Mercury 2
(Date:11/25/2009)...,Nov.25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq:...of-carebloodanalysissystems,announcedtodaythatClin...sentatthe21stAnnualPiperJaffrayHealthCareConferenc...ncewillbeheldattheNewYorkPalaceHotelinNewYorkCity....uresandmarketsportablebloodanalysissystemsforusein...
(Date:11/25/2009)...v.25/PRNewswire/--AccordingtoMillenniumResearchGro...tintelligence,thenearly$3billionUSmarketfortraumaf...extfiveyearsdespitetherecenteconomicslowdown.MRG,s...ismarketwillremainhighlydynamicoverthenextfiveyear...eviouslyunderservedsegmentsofthetraumafixationmark...
(Date:11/25/2009)...Nov.25/PRNewswire/--CempraPharmaceuticalsInc.today...fexecutiveofficer,willpresentatthePiperJaffray21st...2009,atTheNewYorkPalaceHotelinNewYorkCity.Dr.Ferna...ntibioticclinicalprogramsforthetreatmentofdrug-res...armaceuticals ,, Foundedin2006,CempraPharmaceu...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Cancer Advocacy Organization Confronts the Source of rBGH Demands Pharmaceutical Giant Eli Lilly Stop Milking Cancer 57914 1Cancer Advocacy Organization Confronts the Source of rBGH Demands Pharmaceutical Giant Eli Lilly Stop Milking Cancer 57914 2Will Jatropha Become a 26apos 3BDotCom Bubble 26apos 3B in Biofuel Industry 3F Leading to 2nd JatrophaWorld Africa Jatropha Webinar on 30 Sept 09 Ex 14196 1Will Jatropha Become a 26apos 3BDotCom Bubble 26apos 3B in Biofuel Industry 3F Leading to 2nd JatrophaWorld Africa Jatropha Webinar on 30 Sept 09 Ex 14196 2Brain Aneurysm Patients Have A New Voice With Brain Storms Blog 57908 1Brain Aneurysm Patients Have A New Voice With Brain Storms Blog 57908 2Brain Aneurysm Patients Have A New Voice With Brain Storms Blog 57908 3
.../ -- Asenapine -- an,investigational drug being de...unit of Akzo Nobel, for bipolar I disorder and,sch...e than placebo,in treating acute manic and mixed e...ing to new Phase III results, from a study,present...Annual,Meeting. , In the three-week study, patient...
... -, COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-Fi...afety and efficacy of,desvenlafaxine succinate, a ... being studied as a potential treatment for adults...ted today at the,2007 American Psychiatric Associa... Pharmaceuticals, a division of Wyeth . Results,fr...
Other Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
Medicine Products: